Laurie Tuason

1.9k total citations
27 papers, 1.1k citations indexed

About

Laurie Tuason is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Laurie Tuason has authored 27 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Laurie Tuason's work include CAR-T cell therapy research (4 papers), Cervical Cancer and HPV Research (4 papers) and Immunotherapy and Immune Responses (4 papers). Laurie Tuason is often cited by papers focused on CAR-T cell therapy research (4 papers), Cervical Cancer and HPV Research (4 papers) and Immunotherapy and Immune Responses (4 papers). Laurie Tuason collaborates with scholars based in United States, Switzerland and Brazil. Laurie Tuason's co-authors include Eric A. Klein, Ronald M. Bukowski, Howard S. Levin, Caldwell B. Esselstyn, Randall J. Yetman, Mark R. Licht, Robert E. Hermann, Leslie R. Schover, Richard V. Dowden and Sharon Grundfest‐Broniatowski and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and CHEST Journal.

In The Last Decade

Laurie Tuason

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurie Tuason United States	16	467	333	300	221	186	27	1.1k
PHM de Mulder Netherlands	17	504 1.1×	298 0.9×	716 2.4×	62 0.3×	119 0.6×	27	1.2k
Rangesh Kunnavakkam United States	17	249 0.5×	420 1.3×	209 0.7×	41 0.2×	200 1.1×	29	800
Lauren E. Schwartz United States	17	319 0.7×	310 0.9×	349 1.2×	60 0.3×	13 0.1×	58	1.2k
Laura Marandino Italy	19	477 1.0×	360 1.1×	509 1.7×	63 0.3×	14 0.1×	95	1.1k
Janine Bell United Kingdom	10	423 0.9×	113 0.3×	182 0.6×	28 0.1×	265 1.4×	11	1.0k
Michael Moran United Kingdom	13	305 0.7×	237 0.7×	190 0.6×	39 0.2×	288 1.5×	37	882
Jerzy E. Tyczynski United States	15	438 0.9×	291 0.9×	197 0.7×	19 0.1×	48 0.3×	38	1.1k
Vishal Gupta United States	24	636 1.4×	401 1.2×	764 2.5×	85 0.4×	928 5.0×	84	1.7k
Maurizio Mascarin Italy	18	295 0.6×	264 0.8×	103 0.3×	71 0.3×	61 0.3×	86	1.0k
Nabil Ismaili Morocco	17	404 0.9×	125 0.4×	218 0.7×	23 0.1×	44 0.2×	65	724

Countries citing papers authored by Laurie Tuason

Since Specialization

Citations

This map shows the geographic impact of Laurie Tuason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurie Tuason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurie Tuason more than expected).

Fields of papers citing papers by Laurie Tuason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurie Tuason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurie Tuason. The network helps show where Laurie Tuason may publish in the future.

Co-authorship network of co-authors of Laurie Tuason

This figure shows the co-authorship network connecting the top 25 collaborators of Laurie Tuason. A scholar is included among the top collaborators of Laurie Tuason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurie Tuason. Laurie Tuason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Budd, G. Thomas, Peter C. Adamson, Manjula K. Gupta, et al.. (1998). Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.. PubMed. 4(3). 635–42. 69 indexed citations

2.

Klein, Eric A., Patrick A. Kupelian, Laurie Tuason, & Howard S. Levin. (1998). Initial Dissection of the Lateral Fascia Reduces the Positive Margin Rate in Radical Prostatectomy. Urology. 51(5). 766–773. 45 indexed citations

3.

Adelstein, David J., Jerrold P. Saxton, Pierre Lavertu, et al.. (1997). A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head & Neck. 19(7). 567–575. 203 indexed citations

4.

Adelstein, David J., Jerrold P. Saxton, Pierre Lavertu, et al.. (1997). A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head & Neck. 19(7). 567–575. 4 indexed citations

5.

Bukowski, Ronald M., Thomas Olencki, David M. Peereboom, et al.. (1997). Phase II Trial of Interleukin-2 and Interferon-ce in Patients with Renal Cell Carcinoma: Clinical Results and Immunologic Correlates of Response. Journal of Immunotherapy. 20(4). 301–311. 28 indexed citations

6.

Olencki, Thomas, James H. Finke, R Tubbs, et al.. (1996). Immunomodulatory Effects of Interleukin-2 and Interleukin-4 in Patients with Malignancy. Journal of Immunotherapy. 19(1). 69–80. 5 indexed citations

7.

Tuason, Laurie, et al.. (1996). HIV Infection among Brazilian Transvestites in a Prison Population. AIDS Patient Care and STDs. 10(5). 299–302. 15 indexed citations

8.

Wos, Edward J., Thomas Olencki, Laurie Tuason, et al.. (1996). Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer. 77(6). 1149–1153. 19 indexed citations

9.

Tuason, Laurie, G. Thomas Budd, D. Peereboom, et al.. (1996). Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma.. PubMed. 77(6). 1149–53. 23 indexed citations

10.

Kupelian, Patrick, Jerald Katcher, Howard S. Levin, et al.. (1995). 1011 Preoperative and pathologic prognostic factors affecting psa levels after radical prostatectomy alone in men with clinically localized prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 32. 228–228. 1 indexed citations

11.

Schover, Leslie R., Randall J. Yetman, Laurie Tuason, et al.. (1995). Partial mastectomy and breast reconstruction. A comparison of their effects on psychosocial adjustment, body image, and sexuality. Cancer. 75(1). 54–64. 215 indexed citations

12.

Kavuru, Mani S., et al.. (1995). Empiric Prednisone Therapy for Pulmonary Toxic Reaction After High-Dose Chemotherapy Containing Carmustine (BCNU). CHEST Journal. 107(2). 482–487. 17 indexed citations

13.

Lichtin, Alan, et al.. (1995). High-Dose Busulfan and Cyclophosphamide Followed by Autologous Bone Marrow Transplantation and/or Peripheral Blood Progenitor Cell Rescue for Metastatic Breast Cancer. American Journal of Clinical Oncology. 18(6). 491–494. 15 indexed citations

14.

Kennedy, Alexander, Gertrude Peterson, Laurie Tuason, J BELINSON, & Kenneth Webster. (1995). Radical hysterectomy for cervical cancer: the effect of shorter length of stay on outcome. Cleveland Clinic Journal of Medicine. 62(3). 193–197. 2 indexed citations

15.

Licht, Mark R., Eric A. Klein, Laurie Tuason, & Howard S. Levin. (1994). Impact of bladder neck preservationduring radical prostatectomy on continence and cancer control. Urology. 44(6). 883–887. 106 indexed citations

16.

Bukowski, Ronald M., G. Thomas Budd, Jacqueline A. Gibbons, et al.. (1994). Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.. Journal of Clinical Oncology. 12(1). 97–106. 26 indexed citations

17.

Bukowski, Ronald M., James H. Finke, Michael J. Caulfield, et al.. (1994). Phase I Trial of Cisplatin, WR-2721, and the Murine Monoclonal Antibody R24 in Patients with Metastatic Melanoma. Journal of Immunotherapy. 15(4). 273–282. 12 indexed citations

18.

Finke, James H., Patricia Rayman, Jeannine Alexander, et al.. (1994). Characterization of Tumor-Infiltrating Lymphocyte Subsets from Human Renal Cell Carcinoma: Specific Reactivity Defined by Cytotoxicity, Interferon-?? Secretion, and Proliferation. Journal of Immunotherapy. 15(2). 91–104. 48 indexed citations

19.

Kennedy, Alexander, Charles V. Biscotti, William R. Hart, & Laurie Tuason. (1993). Histologic Correlates of Progression-Free Interval and Survival in Ovarian Clear Cell Adenocarcinoma. Gynecologic Oncology. 50(3). 334–338. 22 indexed citations

20.

Olencki, Thomas, G. Thomas Budd, James H. Finke, et al.. (1993). Phase IA/IB Trial of rhIL-6 in Patients with Refractory Malignancies: An Immunomodulatory Cytokine. Journal of Immunotherapy. 14(4). 362–362. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact